Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Therapeutic Focus Areas

Key principles banner image

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Menarini Stories

World COPD Day: from awareness to early action for patients
Categories
menarini-com:blog/en/post-category/our-health

 

A day to raise awareness 

On November 18th, World COPD Day brings attention to chronic obstructive pulmonary disease (COPD), encouraging knowledge sharing and discussion of ways to reduce its  burden worldwide.1

The theme for this year, "Early Diagnosis and Management for a Better Life", draws  attention to a persistent challenge: despite COPD being common, preventable, and  treatable, widespread underdiagnosis and misdiagnosis mean that many patients  receive treatment later in the course of their disease. The theme highlights the  important opportunity to act through prevention, early intervention, and timely  treatment.1

Understanding COPD 

COPD is a complex condition, and environmental factors other than smoking can  contribute to its development.1,2 It usually progresses slowly and becomes noticeable in midlife, but it can also begin earlier and affect young people, especially those  1,2 showing early signs known as pre-COPD or PRISm.

Treating COPD early can help slow its progression, ease the burden of symptoms, and prevent future exacerbations or flare-ups. Early action can include support to  stop smoking, reduction of risk factors, and timely introduction of appropriate therapy. Together, these steps can help protect lung function and improve patients' overall quality of life.1

A global challenge

COPD restricts airflow through the lungs, making breathing more difficult. Also referred to as emphysema or chronic bronchitis, it can cause a persistent cough, sometimes with phlegm, as well as breathlessness, wheezing, and tiredness.2 COPD is a major global health challenge affecting millions of people. In 2021, an estimated 213 million people worldwide were living with the disease.3Its substantial burden is reflected in its current position as the third leading cause of death globally.2

In 2023 alone, COPD was responsible for approximately 3.4 million deaths, representing about 6% of deaths worldwide.2 The toll of COPD draws attention to the important contribution of environmental factors, including air pollution, and reinforces the urgent need for targeted public health action.3

Working together for better COPD care

World COPD Day 2026 conveys an important message: while COPD has no definitive cure, earlier diagnosis and treatment can make a positive difference to future health. Addressing the disease therefore calls for collective action, changes across health systems, and advocacy from everyone.1

Patients and families can call for more research and better access to care, from routine spirometry screening to telehealth services in remote areas. Healthcare providers and policy makers can promote spirometry as a general indicator of health throughout life, while health systems can strengthen academic training in respiratory health and COPD diagnosis. Governments can support these efforts by reducing smoking, improving air quality, encouraging clean energy, and expanding access to early diagnosis and treatment.1

By raising awareness and placing early diagnosis at the forefront, World COPD Day seeks to empower people living with COPD. Its goal is to help build a future in which they receive better support and timely treatment, with greater control over their  1 long-term health.

Menarini Group's commitment to people living with COPD 

Our commitment to COPD care starts with the people living with it.  The Menarini Group aims to encourage earlier detection, address critical unmet  medical needs, and optimize the management of persistent symptoms like fatigue  and chronic cough. Behind each of these efforts is one goal: helping people living with COPD lead healthier,  more fulfilling lives, with the recognition and support they need. 

IM-34-2026 Date of preparation October 2026 

 

Sources: 

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). World COPD Day 2026.

Available at: https://goldcopd.org/world-copd-day-2026/. Last accessed October  2026. 

2. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD) Fact Sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/chronicobstructive-pulmonar y-disease-(copd). Last accessed October 2026.

3. Cao Z. et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2021: results from the Global Burden of Disease Study 2021. BMJ Public Health (2026).